Zyceva contains erlotinib, a targeted cancer therapy used to treat certain types of non-small cell lung cancer and pancreatic cancer. It belongs to a group of medications known as tyrosine kinase inhibitors. Zyceva is taken orally and is usually prescribed when the cancer has specific genetic mutations. It helps in slowing the growth and spread of cancer cells and is commonly used in patients with advanced or metastatic disease.

Mechanism of Action
Erlotinib works by blocking a protein known as the epidermal growth factor receptor, or EGFR. This receptor is found on the surface of many cancer cells and helps them grow and multiply. In cancers where EGFR is overactive or mutated, blocking its signal can stop the cancer cells from growing. Zyceva attaches to the EGFR and stops it from sending signals inside the cell, essentially putting the brakes on tumor growth.

Uses
Zyceva is mainly used in the treatment of:

• Advanced or metastatic non-small cell lung cancer, especially in patients with specific EGFR mutations

• Pancreatic cancer, typically in combination with another chemotherapy medicine called gemcitabine
  Adverse Effects

• Zyceva, like many cancer medicines, can cause side effects. The most common ones include rash, diarrhea, nausea, fatigue, and loss of appetite. The skin rash may resemble acne and usually appears on the face and upper body. These side effects are usually manageable and may even be a sign that the drug is working. More serious but less common side effects include liver problems, eye irritation, lung inflammation, or gastrointestinal bleeding. Patients are often monitored regularly to check for any signs of these complications.